Clinical Research Division
Taipei, 115, Taiwan
NCT Number: NCT00709514
The primary objective of this Phase 2 study is to evaluate the efficacy of DCB-WH1 ointment in wound closure as compared to vehicle control when applied topically to chronic diabetic foot ulcers for 12 weeks. The secondary objective of this study is to collect safety information of DCB-WH1 ointment.
This is a randomized, double-blind, parallel group, vehicle-controlled, multi-center study of DCB-WH1 ointment applied topically to grade 1 foot ulcers (according to Wagner grading system) in 50 subjects with diabetes mellitus.
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Phase 2
Taipei, 115, Taiwan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
DCB-WH1 ointment (1.25%), topically applied twice daily
Placebo
Time frame: 12 weeks
Time frame: 12 weeks
time to ulcer closure, time to half ulcer closure, ulcer closure rate at endpoint, change and percentage change from baseline in ulcer size
Oneness Biotech Co., Ltd.
Industry
A Phase II, Double-blind, Placebo-controlled Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05849701
Chronic Diabetic Foot Ulcer
Cairo, Egypt
View Trial DetailsNCT05338463
Chronic Diabetic Foot Ulcer, Peripheral Arterial Occlusive Disease 1
Taipei, Taiwan
View Trial DetailsNCT06319287
Cardiovascular Diseases, Diabetes Complications
Blue Ash, Ohio, United States
View Trial DetailsNCT07484542
Back Pain, Bronchial Diseases
Islamabad, Pakistan
View Trial Details